Edition:
India

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

8.71USD
20 Apr 2018
Change (% chg)

$-0.04 (-0.46%)
Prev Close
$8.75
Open
$8.72
Day's High
$8.79
Day's Low
$8.55
Volume
7,184
Avg. Vol
59,358
52-wk High
$23.68
52-wk Low
$7.85

Latest Key Developments (Source: Significant Developments)

Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100
Monday, 26 Mar 2018 

March 26 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS.PROTAGONIST THERAPEUTICS - USING PRE-SPECIFIED CRITERIA, DMC DEEMED TRIAL TO BE FUTILE BASED ON AN ANALYSIS OF PRIMARY ENDPOINT OF CLINICAL REMISSION.PROTAGONIST THERAPEUTICS INC - NO SAFETY CONCERNS WERE NOTED IN ANALYSIS.PROTAGONIST THERAPEUTICS INC - ‍DECISION FOLLOWED A PLANNED INTERIM ANALYSIS BY AN INDEPENDENT DATA MONITORING COMMITTEE​.PROTAGONIST THERAPEUTICS- TO POSTPONE DECISION ABOUT INITIATION OF PHASE 2/3 CLINICAL TRIAL OF PTG-100 IN CHRONIC POUCHITIS.PROTAGONIST THERAPEUTICS- TO POSTPONE DECISION ABOUT INITIATION OF PHASE 2/3 CLINICAL UNTIL AFTER FULL REVIEW OF INTERIM DATA FROM UC PROPEL STUDY.  Full Article

Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Protagonist Therapeutics Inc : :Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200.Protagonist Therapeutics - co is developing PTG-200 in collaboration with Janssen.  Full Article

Protagonist Therapeutics Q3 ‍net loss per share $0.29​
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update.Protagonist Therapeutics Inc qtrly ‍net loss per share attributable to common stockholders was $0.29​.  Full Article

Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Prices public offering of common stock.Says public offering of 3.53 million common shares priced at $17.00 per share.  Full Article

Protagonist Therapeutics announces proposed public offering of common stock
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Protagonist Therapeutics Inc :Protagonist Therapeutics announces proposed public offering of common stock.Protagonist Therapeutics -to use proceeds to fund clinical research, development of co's three therapeutic candidates, PTG-100, PTG-200, and PTG-300​.  Full Article

Lilly Ventures Fund I reports 12.9 percent stake in Protagonist Therapeutics Inc as of Aug. 16
Saturday, 27 Aug 2016 

Protagonist Therapeutics Inc : Lilly Ventures Fund I LLC reports 12.9 pct stake in Protagonist Therapeutics Inc as of August 16- Sec filing .Lilly Ventures Fund I LLC reports 12.9 pct stake in Protagonist Therapeutics Inc as of August 16 -Sec filing.  Full Article

Ra Capital reports 6.8 pct passive stake in Protagonist Therapeutics
Friday, 26 Aug 2016 

Protagonist Therapeutics Inc : RA Capital Management LLC reports 6.8 percent passive stake in Protagonist Therapeutics Inc as of August 16 - SEC filing Source: (http://bit.ly/2bDvmY3) Further company coverage: [PTGX.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Adage Capital Partners reports 9.69 pct passive stake in Protagonist Therapeutics - SEC filing
Saturday, 20 Aug 2016 

Adage Capital Partners LP:Adage Capital Partners LP reports 9.69 pct passive stake in Protagonist Therapeutics Inc as of August 11, 2016 - SEC filing.  Full Article

Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing
Friday, 19 Aug 2016 

Johnson & Johnson:Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16.  Full Article

Protagonist Therapeutics shares open at $12.00 in debut
Thursday, 11 Aug 2016 

: Protagonist Therapeutics Inc shares open at $12.00 in debut, flat from the IPO price of $12.00 per share Further company coverage: [PTGX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100

* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS